NY-ESO-1 peptide-pulsed dendritic cell vaccine

NY-ESO-1 peptide-pulsed dendritic cell vaccine is an investigational cancer immunotherapy consisting of autologous dendritic cells loaded (pulsed) ex vivo with synthetic NY-ESO-1 peptides, commonly the immunodominant 157-165 or longer peptide sequences derived from the NY-ESO-1 cancer-testis antigen. The vaccine aims to stimulate a targeted cellular immune response by enhancing presentation of NY-ESO-1 antigens to patient T cells, inducing NY-ESO-1-specific cytotoxic T lymphocytes (CTLs) and helper T cell responses against NY-ESO-1-positive tumors. The approach is used primarily for solid tumors expressing NY-ESO-1, notably melanoma, sarcoma, and other advanced malignancies. Administration is typically by intradermal or intravenous injection. This approach has been investigated in combination with other immunotherapies such as immune checkpoint inhibitors, α-Galactosylceramide (α-GalCer), and adoptive T cell transfer, in both phase 1 and phase 2 clinical trials. No commercial approval has been granted as of 2025, and trials focus on safety, immunogenicity, and preliminary efficacy[1][3][5][6].

Other names

NY-ESO-1 peptide-pulsed DC vaccineNY-ESO1 peptide-pulsed DC vaccineNY-ESO 1 peptide-pulsed DC vaccineNY-ESO-1 long peptide-pulsed DC vaccineNY-ESO1 long peptide-pulsed DC vaccineNY-ESO 1 long peptide-pulsed DC vaccineDCV (NY-ESO-1)NY-ESO-1-pulsed dendritic cell vaccineNY-ESO1-pulsed dendritic cell vaccineNY-ESO 1-pulsed dendritic cell vaccine